SNAPTECH Srl Award at MADE EXPO Milan
Spin Off SNAPTECH SRL (Sustainable Nanoparticles Production and Technologies), represented by Prof. Giuliana Taglieri of the Materials Science and Technology research group, successfully participated in the MADE EXPO event - Milan, (15-18 November 2023), the main Italian event and one of the main ones in Europe for the world of construction, and was awarded First Place in the Start-Up category, receiving the ME AWARDS.
This important award was conferred by a scientific and technical Jury, mainly made up of professors from the Politecnico di Milano and the University of Campania, as well as leading companies in the sector, with the following motivation
"SNAPTECH - Spin Off of the University of L'Aquila, stood out for being the most innovative Start-Up present at the event, which originates from academic research, dedicated to the production of nanoparticles through innovative processes, with low environmental impact and reduced energy consumption, combining technology, innovation and sustainability.
Among the nanoparticles produced, SNAPTECH has developed new-generation nanocalcium (NANOLAQ products), for innovative use in the world of Cultural Heritage, with ad hoc formulations for different application needs".
(Publication date: 27/11/2023)
Univaq patents on the Knowledge-share platform
The Knowledgeshare.eu platform is the largest digital patent platform in Italy, the result of a joint project of the Italian Patent and Trademark Office (DG TPI UIBM), the Polytechnic University of Turin and the Network for the Enhancement of Research (NETVAL - which brings together to date 98 universities and Public Research Institutions, as well as Scientific Hospitalization and Treatment Institutes).
It is a showcase that aims to represent for Italian companies the meeting point with the technological knowledge developed by the research of the university system, public research centers and IRCSS, knowledge sanctioned by patents that can be the subject of concrete industrial application by the economic system. Prospective buyers will find there a vast library with more than 1,500 patents in the database, translated into concise and usable language so as to make them accessible to all, published in dual Italian-English, ready to be transferred to companies and transformed into strengths of their industrial activity and success in the markets - through licensing or commercialization agreements.
Univaq patents are available at the following link
Free intellectual property check-up service
Since 2018, at the initiative of MISE-UIBM, a completely free service has been active for the benefit of companies in the area for the diagnosis, identification, protection and enhancement of intellectual property held by companies, with the aim of providing useful suggestions for its enhancement.
Interested companies can request an appointment directly from the staff of the University of L'Aquila's Office of Technology Transfer.
Once the appointment is scheduled, the company will benefit from a visit by ProMISE-Univaq project staff, lasting up to one hour, for a discussion on the issues of knowledge, protection, management and valorization of industrial property titles.
More information at the following link
The new technology transfer section of the university website is online
The new section of the University website, relating to Technology Transfer, is online; you can find the news in evidence, the services available for businesses and researchers, figures and useful information to consult.
The restructuring of the section was carried out by the staff of the ProMiSE Project, by the staff of the technology transfer sector, under the coordination of Prof. Luciano Fratocchi, Delegate of Rector for technology transfer, third party funded research activities and start-up development.
The University of L'Aquila in foreground in gene therapy for rare bone diseases
SiSaf Ltd, a UK company developing RNA-based therapies for rare genetic skeletal diseases, announced that it has exercised its option to acquire a patent licence from the University of L'Aquila. The licence allows SiSaf to develop a new generation of drugs to treat genetic diseases such as autosomal dominant osteopetrosis type 2 (ADO2). SiSaf and the University of L'Aquila signed the scientific collaboration and licensing agreement last year. The exercise of the licence option follows an intensive 12-month pre-clinical collaborative research that has demonstrated the efficacy and tolerability of the investigational drug [SiS-101-ADO2].